Bionano Genomics, Inc. (BNGO)
| Previous close | 1.0800 |
| Open | 1.0500 |
| Bid | 1.0300 x 100 |
| Ask | 1.0500 x 1400 |
| Day's range | 1.0200 - 1.0780 |
| 52-week range | 0.7100 - 8.2000 |
| Volume | |
| Avg. volume | 1,421,751 |
| Market cap | 69.01M |
| Beta (5Y monthly) | 2.41 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Bionano Announces Three Publications Demonstrating OGM’s Utility for Cell and Gene Therapy
Three peer-reviewed publications collectively illustrate the building support for optical genome mapping (OGM) as a tool for cell and gene therapy development that allows researchers in academic medical centers and biopharmaceutical companies to assess genome integrity in therapeutic cell lines like chimeric antigen receptor-modified T cells (CAR-T), stem cells, and cell lines used for translational research in unraveling genetic causes of Alzheimer’s diseaseTaken together, the publications illu
- GlobeNewswire
Bionano Announces Series of Major Advancements to its Suite of Computational Tools for Comprehensive Cancer Analysis
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced significant upgrades to its suite of computational tools for comprehensive cancer analysis. These advancements to the company’s VIA™ software solution enhance the detection and interpretation of aneusomies, and improve the analysis, visualization, interpretation, and reporting of data types including optical genome mapping (OGM), next generation sequencing, and microarray, for comprehensive assessme
- GlobeNewswire
Bionano Reports First Quarter 2024 Results and Highlights Recent Business Progress
Q1 2024 revenue was $8.8 million, which represents an 18% increase over Q1 2023Total installed base of 347 optical genome mapping (OGM) systems as of Q1 2024, which represents a 34% increase over Q1 2023Sold 8,249 nanochannel array flowcells in Q1 2024, which represents a 58% increase over the number of flowcells sold in Q1 2023Efforts to reduce cash burn and operating expense continued with the March 2024 announcement of expanded cost savings initiatives; since the initial cost savings initiati
